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Communication and Miscommunication in Informed Consent to
Research
Abstract
Biomedical ethics require that research subjects be aware that the drugs they take or procedures they undergo
are designed to fulfill the conditions of the experiment and not to benefit a subject’s health. This apparently
straightforward distinction between research and treatment is a source of much controversy and
misunderstanding. Ethicists have labeled this problem the "therapeutic misconception." This misconception
and, more broadly, informed consent have been studied extensively. Nonetheless, the therapeutic
misconception persists among research subjects. This paper argues that one factor overlooked in the
persistence of the therapeutic misconception is the effect of the theoretical paradigm that guides the practice
and analysis of informed consent. The paradigm poses an idealized model of communication that ignores
social context. This paper examines informed consent practices associated with a cancer research trial to
demonstrate an alternative approach to studying informed consent to research. Through analysis of informed
consent session transcripts, it demonstrates the importance of taking account of not only what is said, but how
and by whom it is said.
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Communication and Miscommunication
in Informed Consent to Research
Biomedical ethics require that research subjects be aware that the drugs
they take or procedures they undergo are designed to fulfill the conditions
of the experiment and not to benefit a subject’s health. This apparently
straightforward distinction between research and treatment is a source
of much controversy and misunderstanding. Ethicists have labeled this
problem the “therapeutic misconception.” This misconception and, more
broadly, informed consent have been studied extensively. Nonetheless, the
therapeutic misconception persists among research subjects. This paper
argues that one factor overlooked in the persistence of the therapeutic
misconception is the effect of the theoretical paradigm that guides the
practice and analysis of informed consent. The paradigm poses an ide-
alized model of communication that ignores social context. This paper
examines informed consent practices associated with a cancer research
trial to demonstrate an alternative approach to studying informed consent
to research. Through analysis of informed consent session transcripts, it
demonstrates the importance of taking account of not only what is said,
but how and by whom it is said. [genetics, biomedical research, informed
consent, biomedical language]
Introduction
Therapeutic Misconception
Informed consent sessions are meetings in which biomedical investigators
discuss details of proposed research with potential subjects. This exchange pre-
cedes enrollment in research and is accompanied by a document, the consent form,
which provides a detailed version of the information that has been discussed. The
form requires a subject’s signature, which, in turn, is meant to represent his or
her voluntary and informed agreement to participate in the experiment being pro-
posed. The informed consent session and form describe the experiment’s risks,
benefits, and alternatives as well as several other conditions, such as the subject’s
right to withdraw from the experiment and confidentiality protections. Among the
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most important requirements for informed consent to research is that the subject
understand that the procedures or medications constitute research, not treatment.
The apparently simple distinction between treatment and research has gen-
erated persistent controversy concerning informed consent to research because
it is often the case that despite going through informed consent, research sub-
jects erroneously believe that they are agreeing to treatment. This confusion,
dubbed the therapeutic misconception, need not hinge on a literal mislabeling of re-
search as treatment; although the word treatment is often used to describe research
(Appelbaum, Roth, and Lidz 1982; Fried 1974). More importantly, it represents
a confusion of goals. Whereas the goal of medical care is symptom relief or cure
for the patient, the goal of research is hypothesis testing for the investigator. Thus,
a patient’s treatment is based on what is best for the patient’s health, while a sub-
ject’s management is based on what is best for, or required by, the research design.
For example, in certain experiments, the drug dosage given to a subject is based
on the cohort to which randomization assigns him or her; in others, it is based on
the order in which the subject enrolls in the research. In neither case is the drug
prescribed or procedure chosen based on an assessment of the individual subject’s
medical needs. The subject’s erroneous belief that it is constitutes the therapeutic
misconception. Informed consent to research is meant to dispel the therapeutic
misconception by explaining to potential subjects that the proposed procedures
are research, not treatment.
Despite two decades of warnings about the need to beware of the therapeutic
misconception, studies show that it continues to be a problem among a wide variety
of research subjects (Appelbaum 2002; Appelbaum et al. 1987; Daugherty 1999;
Emanuel 1995; Freedman 1990; Miller 2000; Vanderpool and Weiss 1987). The
persistence of the therapeutic misconception is often attributed to patients who so
desperately seek treatment that they distort or ignore statements that the proposed
drug or procedure is research and insist on believing that it is being recommended
specifically to benefit them (Ferguson 2003; Sugarman et al. 1998). However, this
explanation, and perhaps the persistence of therapeutic misconception itself, might
have as much to do with the theoretical paradigm underlying informed consent
and its analysis as with the influence of wishful thinking by subjects.
The Transmission Model of Informed Consent
The importance of informed consent to biomedical ethics and the relative
temporal boundedness of the informed consent session and form have made it a
popular research topic. Articles on the topic number in the thousands (Sugarman
et al. 1999).1 Most of these articles provide no explicit theory for the approach to
conducting or improving informed consent that they advocate. Implicitly, however,
most of them rely on a theoretical paradigm dating back a half century (Shannon
and Weaver 1949), called alternately the transmission model, or the sender-receiver
model, of communication. Although the subject of considerable criticism (Fiske
1982), this model persists as a popular commonsense view of communication
generally in U.S. society and specifically within biomedicine.
The transmission model of communication was developed by telecommunica-
tion engineers who sought to conceptualize data transmission in a way that allowed
for its standardized measurement, such as in “bits per second,” and contributed
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to efforts to improve transmission through telephone cables and radio waves. The
model assumes stable senders and receivers and unambiguous messages, as would
be the case if the message itself were an electronic pulse. Successful communi-
cation occurs when the message sent is the message received, or when the exact
number, size, and rate of pulses received matches those sent. Any other result is
a failure and is attributed to “noise” or “distortion.” Introduced as a model for
electronic transmissions, it gained popularity as a way to explain human commu-
nication as well. Applied to people, the model implies that ideal or effective human
communication should mimic the stability and clarity of electronic pulses. As a
result, the model cannot incorporate the influence on social interactions of time,
personal relations, purpose, or expectations, except as sources of noise or distortion.
Implicit reliance on this model has fostered the idea that informed consent
is about the transfer of research trial-related information from the investigator to
the subject. This model casts successful transmission as the endpoint of informed
consent and leads to its evaluation based on measures of extent, accuracy, and
duration of information recall (Booth 2002; Edwards et al. 1998; Mayberry and
Mayberry 2002; Sullivan 1998). Informed consent is not without the need to trans-
fer information, and this model has been productively applied to the topic. For
example, research guided by this model is the source of advice to analyze reading
grade level of informed consent materials as a way to improve informed consent,
as well as of proposals to use different media such as videotapes, illustrations, and
computer programs (Meade 1999; Silva and Sorrell 1988).
A 2002 study that analyzed 272 phase 1 cancer trial consent forms (Horng
et al. 2002) suggests that admonitions to investigators to communicate more clearly
and completely have been taken to heart. The study found that the consent forms
described protocols accurately and made clear that they concerned research, not
treatment. As the authors note, however, improved consent forms do not necessarily
mean that subjects are well informed. Rather, it means that if problems persist in
subject understanding, we need to look somewhere other than to the reading level
or clarity of consent forms.
There is no single theoretical alternative to the transmission model of commu-
nication. Research that implicitly or explicitly rejects it focuses instead on social
context and interpretation. Some of the earliest work on informed consent to re-
search, for example, demonstrated that the setting of informed consent—typically
a hospital or clinic—encourages patients to assume that they are being offered
treatment. (Appelbaum, Roth, and Lidz 1982; Katz 1984; Meisel and Roth 1981).
Other research has examined the pitfalls encountered when applying this model
in non-Western cultures (Kaufert 1990), and more recent studies have examined
the language of informed consent. For example, research has examined the label
“gene therapy” for a set of experiments that test whether a novel procedure can
transfer genetic material to a desired site in the human body. These experiments
have no therapeutic intent, and might more accurately be called “human gene
transfer” research. The use of the word therapy implies treatment where none is
provided (Churchill et al. 1998; Lysaught 1998). Human gene transfer2 research
has also been the focus of an inquiry into how investigators use the word “benefit.”
(Henderson and King 2001). This inquiry shows that sometimes investigators use
it to refer to the popular definition, “something that has a good effect,” as in a
drug that might ease a patient’s symptoms, and, at other times, to refer to a desired
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outcome of an experiment, such as killing tumor cells. Killing tumor cells is also
logically a “good effect.” However, in the world of biomedical research, for “tumor
cell kill” to be labeled a benefit, it need be only large enough to be measured and
not necessarily large enough for the subject to physically experience improvement.
The label of benefit, then, absent an elaboration of what kind of benefit, can imply
vastly different outcomes for a subject.
As this research suggests, the language of informed consent is complex and
multilayered and prone to the kinds of miscommunication that are routine among
people of notably different backgrounds or occupations (McTear and King 1991).
Miscommunication is particularly likely when parties involved in an interaction
have markedly different expectations or goals for that interaction. The transmis-
sion model of communication assumes that sender and receiver share goals and
expectations, otherwise transmission fails. Up to a point, those present at an in-
formed consent session do share expectations. They are there to discuss research
participation. But if we ask participants the classic framing question, “What is
going on here?” subjects and investigators are likely to produce rather different
answers (Bateson 1972).
The subjects in the research trial discussed here are terminally ill and are
eligible for this trial only because they have a cancerous tumor that has recently
recurred. The news of the tumor’s recurrence has been confirmed to the patient
for the first time at the consent session, or announced only a few days or weeks
previously. The implication of the recurrence, that the patient has exhausted known
treatments, is likely to dominate his or her answer to the framing question. The
investigators’ answer is likely to be dominated by the need to enroll subjects in
their experiment. This is not to suggest that the investigators are unsympathetic
to the patient’s plight. They are working to solve this patient’s problem, even if
solutions are likely to be available only to future generations. Rather, the point is to
emphasize the radical disjuncture between the frames that each party sets around
this interaction. What one party is trying to get rid of, what is indeed killing one
party—the tumor—is what the other party needs to continue his or her work:
diseased tissue. Much effort is expended to conceal or sidestep this divergence in
expectations. It is this sidestepping that fosters the therapeutic misconception. The
required circumlocutions supply the misinformation that patients draw on when
they create accounts to sustain the interpretation (or misconception) that they
are being offered treatment. Precisely how this happens varies among research
trials. The investigators’ contribution to the therapeutic misconception in the trial
analyzed here is directly linked to the distinctiveness of phase 1 trials, which will
be described before turning to analysis of the consert session transcripts.
Background and Setting of Research
Phase 1 Trials
A phase 1 trial is the first experiment of a drug using human subjects instead
of animal models. These trials are subject to extensive regulation by the Food and
Drug Administration. They have several features that distinguish them from other
sorts of biomedical research and that directly influence the content and significance
of informed consent.
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First, and foremost, the primary purpose of a phase 1 trial is to determine
whether the experimental drug is toxic to humans and to establish the highest
possible dose a human can tolerate before it becomes toxic. Thus, unlike most
human biomedical experiments, a phase 1 trial does not assess a treatment’s effec-
tiveness. Rather the aim is to discover at what point it becomes harmful.
The second distinct feature is reflected in how a phase 1 trial is designed
to test toxicity. Initially, a very small dose of the new drug is given to a small
number of subjects. This initial dose is calculated at 1/1000 of the dose at which
the animal model experienced toxicity. If no toxicity is observed, more subjects
are enrolled and the dose is increased by a power of 10. If this group withstands
the new dose, then another group is enrolled. Subsequent increases occur un-
til investigators think they have reached the maximum-tolerated dose in humans
(Daugherty et al. 1995). This staging is referred to as “dosing” or “dosing cohorts.”
It is designed to make research move gradually and to give investigators ample
time to detect toxic effects, should they emerge, while their harm to subjects is still
minor.
The third feature is a logical outcome of the dosing design. The effort to min-
imize toxic effects also minimizes all effects. In other words, there is no intended
benefit in these trials. This is true no matter how benefit is defined, whether as in
popular parlance of feeling better or living longer, or in research jargon meaning
reduced tumor size. While lack of benefit is the logical outcome of a phase 1
trial design, its absence remains controversial (Kodish, Lantos, and Seigler 1990;
Lipsett 1982; Markman 1986; Miller 2000; Schain 1994).
A fourth feature, present in only some phase 1 trials, is that the experiment
must be conducted on “sick volunteers,” that is, people who have the disease that
the experimental drug aims to treat. In certain serious diseases, such as advanced
cancer, this requirement carries with it the additional limit of enrolling only pa-
tients who have exhausted all existing treatments. This limitation is based on the
premise that someone with a terminal illness should be allowed to participate in
an experiment only when no other treatment is available. In summary, a phase 1
trial enrolls people, sometimes terminally ill patients, as subjects in experiments
to assess the toxicity to humans of drugs previously tested only in animals.
The phase 1 gene transfer trial reviewed here tested a method for sensitizing
cancerous tumors to respond to treatment by a class of relatively benign drugs. The
trial was designed to assess a technique needed to move the altered genetic material
from test tube to tumor. This transfer is the necessary first step for a novel cancer
treatment based on the hypothesis that a genetically altered virus could trigger
tumor cells to produce a particular protein, which would then sensitize cells to an
existing, approved antiviral drug. This antiviral drug could then be administered to
subjects and, it was hoped, kill the tumor cells in the same way that it kills the virus
against which it was originally designed to act. The advantage of this treatment, if
successful, is that it would provide a way of targeting cancer drugs to a tumor site
and avoid the systemic damage associated with current chemotherapies.
Research Design and Analysis
The analysis presented here is based on observations of 16 informed consent
sessions with potential subjects who were considering enrollment in this trial. The
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consent session observations are part of a larger project examining recruitment
and enrollment in phase 1 trials. Both the cancer gene transfer trial and the study
of research recruitment and enrollment took place at a cancer clinic in a large
university medical center.3 Our inquiry into phase 1 research recruitment and
enrollment began with interviews of patients who were considering enrollment
in research at the cancer clinic. The research nurse who coordinated the patients’
visits identified potential subjects for our study and asked them if they wanted to
participate in an interview about their experience with biomedical research.
Thirty-one patients approached by the research nurse agreed to be inter-
viewed. During these interviews, patients were asked if the interviewer could at-
tend the patient’s informed consent session if the patient decided to pursue research
participation. Of these 31 patients, 16 decided to participate in informed consent
sessions for the gene transfer trial. All 16, in turn, agreed to allow the interviewer
to observe the consent session. The author or a research assistant conducted the
interviews and attended the informed consent sessions.
The investigators who conducted the gene transfer protocol included two on-
cologists, a surgeon, and a medical geneticist. Typically, two or three investigators
were present at each informed consent session. The investigators had previously
consented to be subjects in our study of phase 1 trial recruitment and enrollment and
had agreed specifically to be observed during informed consent sessions for this
gene transfer trial.4 Eleven informed consent sessions were tape-recorded and ex-
tensive handwritten notes were taken for five sessions. The tapes were transcribed
and the notes and transcriptions were entered into a QSR NUD*IST 4 database.
A coding scheme was developed that focused on government-regulated content in
informed consent to research, such as risks, benefits, and trial design. Descriptive
coding such as conducted here minimized the likelihood of coder disagreement.
Each interview was coded by one member of our research team, reviewed by a
second, and a subset of codes checked by a third. Differences among coders were
rare and were resolved through discussions among the coders.
Results
Overview of Informed Consent Sessions
The informed consent sessions typically began with a review of the patient’s
medical history and current state. The investigators discussed with the patient
and his or her family the patient’s symptoms, medication levels, and the size and
location of the tumor. This discussion provided an opportunity for the patient to
ask questions about the condition and for investigators to frame the tumor’s return
as evidence that standard treatment appeared to no longer help the patient.
Once the review of the patient’s condition was complete, the investigators
turned to the availability of options for the patient and introduced the gene transfer
trial. Their opening statement typically included a statement that gene transfer is
experimental, a description of the ideas behind gene transfer, and a description of
what participation would require of subjects.
The length of the opening statement and of the consent session as a whole
often depended on the extent that potential subjects or their family members asked
questions. When there were few questions, the sessions concluded rapidly, often
INFORMED CONSENT TO RESEARCH 435
Table 1
Office of Human Research Protections (OHRP) elements of informed consent to
research discussed in gene transfer trial consent sessions.
Informed Consent Number of Sessions where Percent of
Elements Element Discussed Sessions
Statement that study involves research 16 100
Description of risks 16 100
Description of benefits 16 100
Disclosure of alternative treatments 13 81
Statement of confidentiality 1 6
Explanation of compensation for injury 0 0
Whom to contact with questions 16 100
Statement that participation is voluntary 15 94
Statement of right to withdraw 1 6
with a discussion of how soon the patient could become a subject in the trial.
Other sessions took longer because the family had many questions or because they
introduced topics that the investigators’ did not typically cover (i.e., discussions
of different research protocols or of specific symptoms and how they could be
ameliorated). Potential subjects who raised more questions tended to get more
information about the study design. All of the consent sessions lasted at least a
half hour and several lasted more than an hour. While this is longer than most
informed consent sessions for research, it is not atypical of sessions for novel
protocols, such as gene transfer.
Requirements for Informed Consent to Research
Government regulation of human subjects research5 lists eight basic elements
that informed consent to research must address and several additional elements
that are required depending on certain features of the research. Analysis of the
16 transcripts shows that the sessions covered nearly all of the required elements.
(See Table 1 for a list of the elements of consent that were required for the gene
transfer trial and in how many sessions they were addressed.) All patients were
told that the proposed activity was research, all were told that the benefits of
participation were unknown, and all were told that the research involved risks.
Most of the sessions included a discussion of alternative treatments, conceived of
primarily as other phase 1 trials. The investigators did not use the word voluntary
in consent sessions, but in nearly all of the sessions they indicated that the decision
whether to enter the research trial was up to the patient and his or her family.
There were also elements of informed consent that the researchers did not
routinely address in the informed consent session, including confidentiality, com-
pensation for injury, and whom to contact with questions or in case of injury. The
right to withdraw from the research was mentioned in only one session. All of
these topics, however, were covered in the written informed consent form, as were
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all of the topics described above as having been routinely covered in the consent
sessions.
This analysis indicates that the informed consent sessions met prescribed
standards. Furthermore, the transcripts indicate that for the most part investigators
used fairly simple language. The investigators displayed a consistent willingness
to restate explanations in response to questions and repeatedly encouraged pa-
tients to consider carefully the decision to participate and to discuss the research
with friends, family, and other medical practitioners. However, the problems with
communication in the consent sessions were created less by complex or missing in-
formation, or by time pressure or overt coercion, than by the way that investigators
framed the meaning or apparent significance of certain features of the trial.
Framing
Framing has been used in anthropology, communication studies, and polit-
ical theory to distinguish a certain kind of interaction or to distinguish certain
aspects of interactions (Graber 1989; Marteau 1989; Tuchman 1978). A general
definition might explain frame as the background expectations that we bring to
an interaction, or that motivate an account or a narrative. Framing is the way we
impose those expectations or promote one account over others. At its simplest
level, framing uses inclusion and exclusion to juxtapose and arrange elements in
order to signal or impose a particular account or frame. The concept is useful in
analyzing informed consent interactions because it focuses attention on what is
left out as much as on what is said and because it emphasizes the importance of ex-
amining the expectations that patient and investigator bring to the interaction. The
following sections address the investigators’ contribution to the therapeutic mis-
conception by analyzing how they discuss benefit, the difference between research
and treatment, and dosing.
Benefit. “Rhetorical parity,” a term recently proposed to describe how inves-
tigators discuss research benefits, refers to statements that imply that two outcomes
are equally likely when they are not, such as the possibility of clinical success and
failure (Miller 2000). For example, while the investigators stated in every interview
that the benefit from participation was unknown, they sometimes presented this
information as if that benefit could be substantial. Investigators would say that the
protocol might be beneficial, might have no effect, or might have a detrimental
effect, but not that the chances of benefit were minute, especially for the first group
of subjects enrolled in the trial:
In choosing among the options we have, it is the best. It combines surgery with
a new therapy. There is the potential for additional benefit over surgery. You
can still have other therapies afterwards if this does not work. There are three
possible outcomes. One, you could have no effect. Two, you could have toxic
effects. Three, it could work wonderfully and you’ll live to be 100. I don’t think
that that is going to happen, but those are the options we have to work with. There
are risks, but it is FDA approved [I1G].6
None of the options available will make the tumor go away. In this, this treatment
is not different. It is different in that we do not know the side effects. There is a
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risk to you. You have to balance the risk and the possibility of benefit, small. It
may work, it may not work. You need to ask yourself are these risks acceptable
to me? Given the options, given the risks. [H1O1]
In the first example, the investigator states clearly that the possible risks and
benefits are unknown, but then asserts that the protocol “could work wonderfully
and you’ll live to be 100.” This is a wildly improbable outcome of enrolling in
the lowest dose of a phase 1 clinical trial for a subject with terminal cancer, and
this is information that the researcher knows but does not disclose. In the second
example, the investigator turns the decision over to the subject, which is the correct
procedure for an informed consent session. However, absent an explanation of the
research design, a problem described in more detail in the discussion on dosing
below, the subject has no basis on which to judge whether the experiment “may
work” or “may not work.”
Research and Treatment. In a move similar to rhetorical parity, investigators
blur the difference between “research” and treatment by casting unlike as like.
Investigators referred to the trial as research or as “experimental” in every informed
consent session, however, they did so in a conversational manner that assumed the
meaning of “experiment” was already clear to the subjects.
There’s the risk that we may not be able to get all the tumor out, there’s the risk
that this is an experimental therapy. [S1S]
Another thing that we are doing here, which is a research approach, an experimen-
tal approach to [these] tumors, is something called gene therapy, which involves
injecting a virus that carries a certain gene into the tumor then removing the tumor
a week later. [X2O1]
This gene therapy is a new way of treating [this kind of] tumors. It’s experimental.
We don’t know if it’s going to be good. . . . Now when we say that this is new we
mean that it is experimental. [Q1O1]
You would have the tumor removed so you would have that part of the treatment
and then you would have the additional treatment of the gene treatments plus the
drug. [X2G]
Although each of these statements mentions that what is being proposed is
research or is experimental, the significance of this fact is left unstated (examples
#1 and #2), or it is explained simply as something “new” (example #3), or as an
add-on to standard treatment (example #4). Most often when investigators referred
to the protocol as experimental, they used the label as a way to explain why its
benefits were unknown (in 14 of 16 sessions) (example #3) or why its risks were
unknown (in eight of 16 sessions) (example #1), not to explain that there would
be no benefit.
A misunderstanding between treatment and research is especially likely when
a trial involves both therapeutic and experimental procedures or medications. When
this is the case, the investigator needs to cover two contrasting topics in the in-
formed consent session: (1) recommending a particular avenue of therapy; and (2)
raising the possibility of enrolling in a research trial (which includes the therapeutic
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procedure as one part). This trial called for two surgeries, one to administer a drug
directly into the tumor and one to remove it. The second surgery is both part of
the research and a standard procedure for patients at this stage of disease. This
“debulking” surgery provides temporary symptom relief but has no curative effect.
In nine of the 16 consent sessions, the investigators refer to surgery as beneficial
without specifying which surgery.
At the time of the second surgery the surgeon takes out as much tumor as he can
and he injects another dose of the virus into the remaining tumor cells, the tumor
bed. In your case the tumor is fairly large so we definitely could not get it all out
but he would get out some of it. And that could be a benefit to you just to debulk
the tumor. [A2S]
There is no question that removing some of the tumor if you can get a reasonable
amount out does prolong life in this particular disease. [C2O1]
Just removing the bulk of this can give you more time. Whether the virus in
addition adds anything to that, we still don’t know. It’s still much too soon to say
that. [K2G]
As the third example shows, the investigators often contrasted the known
benefit of removing the tumor with the unknown benefit of the gene transfer trial.
However, they did not always make clear the benefits of debulking surgery alone
or whether the patient could have that surgery without participating in the trial.
Dosing. In studies of clinical trial informed consent, a subject’s understand-
ing of randomization is often taken as evidence of a broader understanding of the
difference between research and treatment. This assumption is based on the rea-
soning that if a subject grasps that his or her assignment to a particular medication
or procedure is by chance, he or she is also unlikely to think that the regimen
will be of direct benefit. For this reason, some consent forms now include a de-
tailed explanation of randomization. The design of phase 1 trials prevents the use
of randomization, and instead subjects are enrolled in dosing cohorts. Including
an explanation of these cohorts and of dose escalation in phase 1 trial informed
consent has been recommended (Freedman 1990), but happens only rarely (Horng
et al. 2002).
The key to the research design of a phase 1 trial is that the first group of
patients is given a very low dose and that then the dose for each subsequent group
is increased by a power of 10. A complete explanation of the research design
requires explaining the entire design, regardless of which group the subject will
be enrolled in. A partial explanation would be to describe only the dose given to
the group that the subject will be enrolled in, perhaps also the dose of the previous
group, but to omit saying that a higher dose will be given to subsequent groups.
The complete explanation of dosing would make clear that the dose being given
to the subject was based on the objective of the experiment—to identify the limits
of toxicity—not the medical needs of participants.
Dose was mentioned in 11 of 16 informed consent sessions. (A summary of
the pattern of dose level and discussion of dose is provided in Table 2). None of
the prospective subjects for the lowest dosing level were told that multiple dosing
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Table 2
Dose level and statements to subjects about risk and benefit.
Multiple Told Lower Told Higher
Dose Total Dosing Doses Dose Equals Dose Might Mean
Level Enrolled Mentioned Discussed Less Risk More Benefit
Lowest (1) 6 4 0 3 0
Middle (2) 7 4 3 1 2
Highest (3) 3 3 3 0 3
levels existed. This was the case also for one of four prospective subjects at the
middle level, but for none at the highest level.
Only one subject entering at the lowest dose was told the reason for starting
with a low dose was, “for safety’s sake.” More typically, investigators mentioned
dose to this cohort as a way to assert that the study was unlikely to be risky. For
example, during an exchange explaining the objective of the consent session, the
patient’s spouse queried: “So, it’s [gene therapy] new here?” One of the oncologists
answered that several similar studies were being conducted at the cancer center
right then, and the second oncologist added,
Oh, yes. We have another cancer gene therapy trial here where they’re going to
be getting a thousand times the dose of the drug that you’re getting. So you really
don’t have to worry about the dosage. [N1O2]
During another session with a subject eligible for the lowest dose, the genetics
researcher contrasted chemotherapy’s systemic toxicity with the targeted effect of
gene therapy and cast as reassuring the low dose this subject would receive.
Well, in animals receiving doses 100 to 1000 times more that you would get, they
did OK. The virus went into normal tissue and they were fine. No animals died.
[K1G]
These statements from the lowest dose sessions address dosing without ex-
plaining its significance by leaving out two important pieces of information. First,
the investigators did not inform the subjects that they would be receiving lower
doses than future study participants. While they point to animals and participants
in other human studies receiving much higher doses, they do not explain why the
dose they are proposing to give to these subjects is so much lower. Second, while
investigators used dosage to stress the low risk to this cohort, they left out the
corresponding implication that a low dose meant a low probability of benefit.
In contrast, when dose was discussed with patients receiving higher doses,
researchers stated that they expected the higher dose to have greater potential
benefit:
It works incredibly well in the test tube, it works incredibly well in animals, but
people are different. We can’t find out until we treat enough patients. We have
treated three patients at the lowest dose of the virus. The next patient that we treat
will get a higher dose of virus and we really think that that’s likely to be effective.
[Y2G]
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We started this at a very low dose of the virus to be safe. We had three patients
at the lowest dose, three patients at the next dose and so forth. So we are now
getting up to doses where we think there is a better chance of really controlling the
tumors. The patients at the lowest dose all had regrowth of tumors. The patients at
the next dose some of them are doing fine. They are all living. Some of them are
doing fine. Some of them have had the tumors grow back. And then the very high
dose, the highest dose, we are just beginning to follow those patients. [K3O1]
And we are now reaching doses of the virus where we expect if there is going to
be some benefit; we will begin to see it. We have treated most of the patients at
lower doses. We gradually increased our dose for reasons of toxicity. And the one
thing we can definitely say is that there is no unusual toxicity. . . . So we don’t
anticipate any problems; we cannot yet say if our treatment is affecting the tumor
growth. Some of the patients have had tumors grow back, some have not. But
they have all been at, except for one patient, they have all been at the lower doses.
[L3O2]
Subjects slated to receive the lowest dose were not told that future subjects
would receive higher doses and subjects slated to receive the highest were not told
that a higher dose entailed greater risk. Interestingly, dose was least often men-
tioned in sessions with subjects slated to receive the second or middle dose level,
perhaps because it was least clear to investigators how best to use the information
about dosing.
By selectively emphasizing certain features to certain patients, investigators
were able to transform the experiment’s dosing design into a desirable feature for
all groups, despite its rather different real implications for each group. Explanations
of how the trial fit into the larger picture of the approval of experimental therapies
followed a similar pattern. For example, when investigators mentioned the FDA, it
was not to explain its role determining the safety of the experimental procedures.
Rather, investigators were more likely to describe the involvement of the FDA as
evidence that the current study is safe. In an exchange between the surgeon and a
patient concerning possible side effects of the trial, the patient followed up on a
comment made by one of the oncologists about the risk that the altered virus, once
injected in the tumor, could spread to other parts of the body, to which the surgeon
replied:
Right, that’s always a theoretical concern. The practicality is that, it’s. . . . We’ve
not seen it in any of the animal studies or any of the humans treated thus far. But
you know the FDA, you have to cover all bases. [A2O1]
Similar references to the FDA occurred in these passages:
FDA has standards, and we get their approval at every stage, even though we
don’t have to, we do. They are the top standard for safety. So you don’t have to
worry about everything being as safe as it can be. [N1O2]
Anyway and you know and I know there’s a lot. You have to have gone a long
way before you can even get the FDA approval on people. [E3O1]
While the FDA requires phase 1 trials to determine whether a new drug is
toxic, the researchers refer to the FDA to reassure patients that the experimental
drug won’t be too risky. While statements about a drug being “not toxic” and “not
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risky” are similar, they are not the same. The choice to frame statements in terms
of “reducing risk” rather than “determining toxicity” allows investigators to refer
to the FDA drug approval process as a protection without directly explaining the
implications of the stage in the approval process at which subjects are recruited.
Mixing the Unproven with the Known
Descriptions of the actual procedures that the subject will undergo are the
source of additional confusion in the consent sessions. Certain steps in the experi-
ment can be described accurately in declarative statements, such as “We give five
different injections with the needle,” because they are known routines, well under-
stood and controlled by the investigators. The combined effect of all of the steps,
however, is unknown. Indeed, determining the combined effect is the objective
of the experiment. Will the “five different injections with the needle” deliver the
altered gene into the tumor? Will the tumor cells absorb it? And will, or at what
point will, its effects become toxic? Sometimes investigators signal the distinction
between the certainty of each procedural step and the speculative nature of the sum
of the steps, or the trial’s outcome, by using the word hope, as in, “we are hoping
that we are injecting this gene into tumor cells.” But just as often, investigators
slide between the known and the unknown without indication.
The following passage opens with a declarative statement about the hypothe-
sized role of the virus—that the virus will successfully transfer the altered gene into
the tumor cells. The next two sentences signal the contingency of this result with
the words hoping and hope. The next 11 lines describe the method being tested—
whether the altered virus can be transferred by injection into the tumor site, whether
the tumor (but not the surrounding tissue) will absorb the injection of altered virus,
whether this absorption will lead the tumor to become sensitive to the chosen antibi-
otic and whether, when the antibiotic is administered, the result of this sensitization
will be that the destruction of tumor cells by the antibiotic. Interspersed in the de-
scription of the hypothesized effects are factual, descriptive statements, such as,
“It is an antibiotic.” The passage ends with a summary of the experiment and the
intended outcome as killing tumor cells—not assessing toxicity—this time pref-
aced by the words, “we believe,” which underscore the investigators’ confidence
in the outcome. (Italics indicate hypothesized results of procedures.)
This virus is carrying a gene, it acts as a vector, or a carrier to carry a certain
gene, a bit of genetic material. When we inject it, we are hoping that we are
injecting this gene into tumor cells. We can’t inject it into every single tumor cell
but we hope that we are getting enough tumor cells. That gene that we are giving
you permits the tumor cells that get injected to make a protein called thymidine
kinase. That protein makes the cells sensitive to a drug. We give that drug in
the vein. When it gets to the tumor cells that have this new gene, those cells die.
So there is a reaction with this drug and that gene. The rest of the cells in your
body that don’t have that gene are not affected by this drug, so the drug is safe
except to the cells that have that gene. So we are changing the tumor cells in
such away that they will be killed off by this drug. It’s not a chemo drug. It is an
antibiotic that kills off [altered] viruses and we are giving you a [altered] virus
gene into those cells to fool those cells into behaving like [altered] viruses so
when this drug comes in it kills them just as though they were [altered] virus
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cells. We believe that once that gene is in there and it produces this protein that
that protein spreads out among the other tumor cells that weren’t injected then
those cells around it can also be killed. [Y2G]
In this consent session, the investigator explains why and how he thinks
gene transfer might work to kill tumor cells. This explanation belongs in the
consent session, but by intermixing statements about steps in the experiment with
statements about what he eventually hopes gene transfer protocols will achieve,
he is framing the contingent as the inevitable. He creates a picture of effectiveness
that undermines concurrent statements that the investigators don’t know whether
the gene transfer will be beneficial. Furthermore, such passages focus attention on
future therapeutic outcomes, obscuring any reminder that the trial’s objective is to
assess toxicity in humans. The difference between the known and the unproven is
further blurred in other consent sessions when investigators switch from talking
about “the tumor” and “the cells” to describing the hypothesized effects of gene
transfer to “your tumor” and “your cells. This change personalizes the description
of what the gene transfer trial might do and suggests that the investigator believes
that it will do these things for this subject.
Conclusion
Therapeutic misconception was identified more than 20 years ago and de-
scribed as an urgent problem that needed fixing. Repeated attempts have been
made to improve informed consent and to mitigate this misconception. These at-
tempts apparently have had some influence on reducing the complexity of consent
forms (Horng et al. 2002). At the same time, recent research suggests that more
than 70 percent of subjects enrolled in a wide variety of trials continue to confuse
the goal of research with the goal of treatment (Appelbaum 2002). This outcome
suggests that some of the efforts to improve informed consent to research might
have misidentified their target. Therapeutic misconception focuses attention on
the subject. Misconception implies misinterpretation and misinterpretation sug-
gests that the problem lies with the party receiving or interpreting the message.
Review of consent session transcripts, however, confirms the need to examine the
investigators’ contribution to misunderstanding.
Investigators play an active role in creating and sustaining the confusion
between research and treatment and precisely how and why they do this begs ex-
amination. As for how they do it, this article showed that investigators discussed,
without explaining, several important topics, including benefit, the difference be-
tween treatment and research, and dosing. They do this by casting unlikely out-
comes as plausible, alternating between the scientific and popular meanings of
terms, and selectively highlighting different features of the proposed trial.
Why investigators foster therapeutic misconception among subjects is not a
question pursued by this research, but is important to address. The question sug-
gests that it might be intentional. Deliberate deception by researchers desperate
to enroll subjects might play a role in a small number of cases, but reducing this
phenomenon to trickery or scapegoating researchers ignores its complexity. Still,
intentionality introduces the question of awareness, and this is a more difficult
issue. Could these researchers have said what they said and not have been aware
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that they were misleading subjects? One answer could be that they were not aware
because they believed that the experiment really would benefit the patients—that
the investigators suffered from their own therapeutic misconception. This inter-
pretation has begun to surface in the literature (Appelbaum 2002; Joffe and Weeks
2002; Miller 2000). Further research might examine how investigators assemble
and sustain their own therapeutic misconception and to what extent it varies in dif-
ferent research settings or with different subjects. Developing this interpretation
would require explaining how investigators integrate what they know about dosing
and randomization into formulations about the likelihood of subject benefit. This
explanation could provide a useful starting point for a practical account of the
rational and irrational features of scientists’ beliefs about risk.
Alternatively, the answer might be that these researchers could have said what
they said and not have been aware that they were misleading subjects because their
assumptions about communication are similar to those of the transmission model
of communication. If investigators think of the consent session as Table 1 charac-
terizes it—as a list of points to review—the fact that they covered virtually all of the
relevant features would constitute a valid informed consent. This interpretation cor-
responds with a common theory of scientific or biomedical language as powerful
because it is capable of achieving objectivity through precision, clarity, and rigor
(McCullough 1989). This theory insists on the primacy of the descriptive function
of language, which is at once a source of the remarkable power of the scientific
method—sustaining the capacity to replicate and extend findings—and a source
of comfort to investigators, in that its objectivity and precision provide a sense of
control over the language, which perhaps extends to a sense of control over the
experiment. Investigators can soothe doubts they might have about exposing peo-
ple to experimental procedures with the knowledge that they have described what
the experiment requires, using words and phrases that in scientific communication
signal “this is research” and that the rest of what is said is just so much noise.
NOTES
Acknowledgments. The larger research project of which this study was one part was
conceived and conducted by a team of researchers, including the author, Mildred Cho,
of Stanford University, and Paul Root Wolpe, of the University of Pennsylvania. Jennifer
Klosinski and Sara Wilcox assisted in data collection and analysis.
1. A MEDLINE search conducted on August 21, 2003, found 4,623 articles with the
words “informed consent” in the title. (For a more select list see Sugarman et al. 1999).
2. I use the phrase “gene therapy” when discussing how investigators presented the
protocol analyzed here because this is the phrase investigators used. Elsewhere, the phrase
“gene transfer” or “human gene transfer” will be used to describe the research.
3. To preserve the confidentiality of the subjects and the investigators, the exact type
of cancer is omitted here, as well as the name of the hospital where the research occurred.
4. The research reported on here received IRB approval from the University of
Pennsylvania and all subjects, including subjects in the gene transfer trial and investigators
who ran the trial, provided informed consent to their participation.
5. Government regulation of human subjects research is overseen by the Office of
Human Research Protections (OHRP) and the mandated requirements for informed consent
are given in the Code of Federal Regulations, Part 46, Protection of Human Subjects, often
referred to as the “Common Rule.”
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6. Passages quoted are identified by a code that denotes the subject, the dose level to
which he or she was assigned, and the investigator making the comment. Subjects are de-
noted by randomly assigned letters of the alphabet and dose levels are denoted by 1, 2, or 3.
Investigators are identified as follows: the surgeon by “S,” the medical geneticist by “G,” and
the two oncologists by “O1” and O2.” Thus, the identification code “B2S” refers to a com-
ment made by the surgeon, about subject “B,” who was enrolled at the second dosing level.
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